Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibody and use methods thereof
The combination of leucine and trileucine in the dry powder formulation solved the problem of lung delivery of anti-TSLP antibodies, enabling effective treatment of asthma patients in primary care settings, reducing adverse reactions, and improving compliance.
JP2025169423APending Publication Date: 2025-11-12MEDIMMUNE LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025140274
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-10-28
- Filing Date
- 2025-08-26
- Publication Date
- 2025-11-12
AI Technical Summary
Technical Problem
Existing technologies make it difficult to deliver anti-TSLP antibodies to asthma patients via an effective pulmonary route, especially those managed in primary care settings, and systemic administration may lead to adverse reactions.
Method used
Develop a dry powder formulation comprising an anti-TSLP antibody-binding fragment in particulate form, leucine, and trileucine, suitable for pulmonary delivery via a dry powder inhaler.
Benefits of technology
It enables efficient delivery of anti-TSLP antibodies in primary care settings, reduces adverse reactions to systemic administration, improves patient compliance, and increases treatment coverage for asthma patients.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2025169423000032 
Figure 2025169423000033 
Figure 2025169423000034
Abstract
To provide dry powder formulations of antigen-binding fragments derived from a thymic stromal lymphopoietin-specific antibody.SOLUTION: Disclosed is a dry powder formulation comprising a plurality of microparticles, where the microparticles comprise: a. 8-11 wt.% of leucine; b. 2-4 wt.% of trileucine; and c. an antigen-binding fragment of an anti-thymic stromal lymphopoietin antibody.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art